Erythropoietin and Peritoneal Dialysis: The Efficacy of Intraperitoneal Dosing

Nissenson A.R. , Nimer S.D. , Wolcott D.L. Recombinant human erythropoietin and renal anemia: Molecular biology, clinical efficacy, and nervous system effects. Ann Intern Med 1991; 114(5): 402–16.

Eschbach J.W. , Abdulhadi M.H. , Browne J.K. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992–1000.

Nissenson A.R. Recombinant human erythropoietin: Impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol 1989; 9(Suppl 2): 25–31.

Wolcott D.L. , Marsh J.T. , La Rue A. , Carr C. , Nissenson A.R. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989; 14: 478–85.

Delano B.G. Improvement in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989; 14(Suppl 1): 14–18.

Marsh J.T. , Brown W.S. , Wolcott D.L. r-HuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991; 39: 155–63.

Zimmerman S.W. , Johnson C.A. Erythropoietin use in peritoneal dialysis patients. Am J Kidney Dis 1991; 17(4)(Suppl 1): 38–41.

Lindblad A.S. , Nolph K.D. Hematocrit values in the CAPD/CCPD population: A report of the National CAPD Registry. Perit Dial Int 1990; 10: 275–8.

De Paepe M.B.J. , Schelstraete K.H.G. , Ringoir S.G. , Lameire N.H. Influence of continuous ambulatory peritoneal dialysis on the anemia of end-stage renal disease. Kidney Int 1983; 23: 744–8.

Saltissi D. , Coles G.A. , Napier A.F. , Bentley P. The hematological response to continuous ambulatory peritoneal dialysis. Clin Nephrol 1984; 22: 21–7.

Mehta B.R. , Mogridge C. , Bell J.D. Changes in red cell mass, plasma volume and hematocrit in patients on CAPD. Trans Am Soc Artif Intern Organs 1983; 29: 50–2.

Summerfield G.P. , Bellingham A.J. , Manlove L. Erythropoietin metabolism in patients on hemodialysis and continuous ambulatory peritoneal dialysis. Clin Sci 1982; 62: 479–88.

Lameire N. , Matthys S. , De Paepe M. Red-cell survival in patients on continuous ambulatory peritoneal dialysis. Perit Dial Bull 1986; 6: 65–8.

Wideroe T.E. , Sanengen T. , Halvorsen S. Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis. Kidney Int 1983; 16(Suppl): S208–17.

Korbet M. , Vonesh E.F. , Firanek A. The effect of hematocrit on peritoneal transport. Am J Kidney Dis 1991; 18(5): 573–8.

Richmond D. , Reft C. , Poseno M. What will EPO do to ultrafiltration (Abstract)? Perit Dial Int 1991; 11(Suppl 1): 226.

Hutchison A.J. , Ofsthun N.J. , Howarth D. , Gokal R. The effect of hemoglobin concentration on peritoneal mass transfer and drain volumes in continuous ambulatory peritoneal dialysis. Perit Dial Int 1992; 12: 230–3.

Taylor J.E. , MacTier R.A. , Henderson I.S. , Belch J.J.F. , Stewart W.K. Dialysis efficiency in continuous ambulatory peritoneal dialysis patients treated with erythropoietin. Perit Dial Int 1992; 12: 221–6.

Nissenson A.R. , Swartz R. , Zimmerman S.W. , Watson A. Epogen study group: A double-blind, placebo-controlled study of recombinant human erythropoietin (EPO) in peritoneal dialysis (PD) patients (Abstract). J Am Soc Nephroll: 405.

Lui S.F. , Law C.B. , Ting S.M. , Li P. , Lai K.N. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1991; 36(5): 246–51.

MacDougall I.C. , Roberts D.E. , Neubert P. , Dharmasena A.D. , Coles G.A. , Williams J.D. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989; 425–7.

Bargman J.M. , Breborowicz A. , Rodela H. , Sombolos K. , Oreopoulos D.G. Intraperitoneal administration of recombinant human erythropoietin in uremic animals. Perit Dial Int 1988; 8: 249–52.

Boelaert J.R. , Schurgers M.L. , Matthys E.G. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1989; 9: 95–8.

Lui S.F. , Chung W.W. , Leung C.B. , Chan K. , Lai K.N. Pharmacokinetics and pharmacody namics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1990; 33: 47–51.

Bargman J.M. , Jones J.E. , Petro J.M. The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate. Perit Dial Int 1992; 12: 369–72.

Frenken L.A.M. , Struijk D.G. , Coppens P.J.W. , Tiggeler RGWL , Krediet R.T. , Koene R.A.P. Intraperitoneal administration of recombinant human erythropoietin. Perit Dial Int 1992; 12: 378–83.

Nasu T. , Mitui H. , Shinohara Y. , Hayashida S. , Ohtuka H. Effect of erythropoietin in CAPD patients: Comparison between intravenous and intraperitoneal administration. Perit Dial Int 1992; 12: 373–377.

Struijk D.G. , Koomen G.C. , Krediet R.T. , Ariaz L. Accuracy of erythropoietin determination in dialysate of CAPD patients. Perit Dial Int 1990; 10: 184–5.

Granollera C. , Branger B. , Beau M.C. , Deschodt G. , Alsabadani B. , Shaldon S. Experience with daily self administered subcutaneous erythropoietin. In: Baldamus C.A. , Scigalla P. , Wieczorek L. , Koch K.M. , eds. Erythropoietin: from molecular structure to clinical application. Contrib Nephrol 1989; 76: 143–8.